At a glance

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

New Molecular Entity
Yes

Highest Development Phases

Preclinical
Cancer; Viral infections

Most Recent Events

01 Nov 2017
AvidBiotics splits itself into two companies, Xyphos to Develop Cell-based Therapeutics for Cancer and Pylum Biosciences that will focus on antibacterial proteins for microbiota management and drug-resistant bacteria